Components of clinical trials for vasovagal syncope

被引:20
作者
Sheldon, R [1 ]
Rose, S [1 ]
机构
[1] Univ Calgary, Hlth Sci Ctr, Fac Med, Cardiovasc Res Grp, Calgary, AB T2N 4N1, Canada
来源
EUROPACE | 2001年 / 3卷 / 03期
关键词
vasovagal syncope; tilt-table test; randomized clinical trials; quality of life; cost utility; drug therapy; pacemaker therapy;
D O I
10.1053/eupc.2001.0168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The time is ripe for adequately powered, randomized, placebo-controlled clinical trials in vasovagal syncope. Vasovagal syncope is a common syndrome, the symptoms of which can be troublesomely frequent. Ii is usually diagnosed by tilt-table testing, although this has persistent problems with both sensitivity and specificity. patients with syncope and positive tilt tests have been the subjects of numerous studies of natural history, risk stratification, and treatment. This payer discusses studies of treatments for vasovagal syncope in the context of a classification of the levels of evidence that can be gleaned from clinical studies. The reasons for placebo-controlled trials al e reviewed, as is the evidence for various methods of risk stratification. Data for power calculations are presented for the primary outcome, the time to the first syncope recurrence. Strengths and weakness of the four main types of outcomes for clinical trials are compared. (C) 2001 The European Society of Cardiology.
引用
收藏
页码:233 / 240
页数:8
相关论文
共 42 条
[11]  
ECTOR H, 1999, PACING CLIN ELECTROP, V21, P193
[12]  
Englund A, 1997, CIRCULATION, V95, P951
[13]   COST AND HEALTH IMPLICATIONS OF CHOLESTEROL LOWERING [J].
GOLDMAN, L ;
GORDON, DJ ;
RIFKIND, BM ;
HULLEY, SB ;
DETSKY, AS ;
GOODMAN, DS ;
KINOSIAN, B ;
WEINSTEIN, MC .
CIRCULATION, 1992, 85 (05) :1960-1968
[14]  
Grimm W, 1997, EUR HEART J, V18, P1465
[15]   Usefulness of transdermal Scopolamine for vasovagal syncope [J].
Lee, TM ;
Su, SF ;
Chen, MF ;
Liau, CS ;
Lee, YT .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 78 (04) :480-&
[16]   IMPAIRMENT OF PHYSICAL AND PSYCHOSOCIAL FUNCTION IN RECURRENT SYNCOPE [J].
LINZER, M ;
PONTINEN, M ;
GOLD, DT ;
DIVINE, GW ;
FELDER, A ;
BROOKS, WB .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1991, 44 (10) :1037-1043
[17]   RECURRENT SYNCOPE AS A CHRONIC DISEASE - PRELIMINARY VALIDATION OF A DISEASE-SPECIFIC MEASURE OF FUNCTIONAL IMPAIRMENT [J].
LINZER, M ;
GOLD, DT ;
PONTINEN, M ;
DIVINE, GW ;
FELDER, A ;
BROOKS, WB .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1994, 9 (04) :181-186
[18]   Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population:: A prospective, double-blind, randomized and placebo-controlled study [J].
Madrid, AH ;
Ortega, J ;
Rebollo, JG ;
Manzano, JG ;
Segovia, JG ;
Sánchez, A ;
Peña, G ;
Moro, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) :554-559
[19]   RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ORAL ATENOLOL IN PATIENTS WITH UNEXPLAINED SYNCOPE AND POSITIVE UPRIGHT TILT-TABLE TEST-RESULTS [J].
MAHANONDA, N ;
BHURIPANYO, K ;
KANGKAGATE, C ;
WANSANIT, K ;
KULCHOT, B ;
NADEMANEE, K ;
CHAITHIRAPHAN, S .
AMERICAN HEART JOURNAL, 1995, 130 (06) :1250-1253
[20]   Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result [J].
Malik, P ;
Koshman, ML ;
Sheldon, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (06) :1284-1289